Body Weight, Bone Diseases, Metabolic, Diabetes Mellitus, Diabetes Mellitus, Type 2, Fall, Fractures, Bone, Musculoskeletal Diseases, Obesity, Osteoporosis, Osteoporotic Fractures, Quality of Life
Conditions
Keywords
Advanced glycation end products, Advanced imaging, Mobility, Strength
Brief summary
Background: Osteoporotic fractures are a major public health issue. They cause substantial disability, loss of autonomy, morbidity and excess mortality. Diabetes is also associated with increased risk for falls and fractures through a direct impact of elevated blood glucose on the skeleton and on muscles. Research project overview: The investigators propose a cross-sectional study that will involve 2 research centers in the province of Quebec. The investigators will recruit 20 obese participants, without diabetes, who have not undergone bariatric surgery, for one-time measurements to be compared with baseline measurements (pre-surgery) from participants in the bariatric obese diabetic groups with type II diabetes mellitus from the ongoing study BODI study (NCT03455868). Bone Mineral Density as well as muscle quality, strength and function will be evaluated at a single study visit. Relevance: This data will permit the evaluation of the bone-muscle unit in patients with obesity with and without diabetes, and assess whether the presence and duration of diabetes impacts further on clinical and functional musculoskeletal outcomes (falls, fractures and mobility and strength) in this population. AGEs, if associated with muscle and bone deterioration, might become an easily accessible biomarker of musculoskeletal health in the clinical setting.
Interventions
None listed
Sponsors
CHU de Quebec-Universite Laval
Suzanne Morin
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
A) Diabetic group * BMI \>=35 kg/m2 * Clinical diagnosis of type 2 diabetes * Use of oral hypoglycemic agents or insulin or 2 of the following tests confirming type 2 diabetes: HbA1c \>=6.5%; fasting glucose \>=7.0 mM; 2-h glucose post 75g oral glucose tolerance test (OGTT) \>=11.1 mM) B) Non-diabetic group: * BMI \>=35 kg/m2 * Normoglycemia (HgbA1c \<5.7% and Fasting glucose \<5.6 nM)
Exclusion criteria
* BMI \>60 kg/m2 * Clinical diagnosis of type 1 diabetes * Disease (e.g. uncontrolled thyroid disease, malabsorptive or overt inflammatory disorder, metabolic bone disease, creatinine clearance \<60 ml/min) * Medication (e.g. gluccocorticoids, anti-epileptic drugs, osteoporosis therapy and thiazolidinediones) affecting bone metabolism * Pregnancy * History of oesophageal, gastric, digestive or bariatric surgery * Prosthesis that could interfere with interpretation of imaging data * Chronic severe condition or illness precluding from participation in the project.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle size measured as cross-sectional muscle area at the proximal femur | Baseline | Measured by quantitative computed tomography (QCT) |
| Muscle composition measured as muscle fat content at the proximal femur | Baseline | Measured by quantitative computed tomography (QCT) |
| Volumetric bone mineral density (vBMD) at the spine, hip, radius and tibia | Baseline | Measured by quantitative computed tomography (QCT) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Insulin like growth factor-1 concentration | Baseline | Hormone involved in bone metabolism |
| Sclerostin concentration | Baseline | Hormone involved in bone metabolism |
| Adiponectin concentration | Baseline | Hormone involved in bone metabolism |
| Leptin concentration | Baseline | Hormone involved in bone metabolism |
| N-terminal propeptide of type 1 procollagen concentration | Baseline | Serum bone formation marker |
| Osteocalcin (total and decarboxylated) concentration | Baseline | Serum bone formation marker |
| Bone specific alkaline phosphatase concentration | Baseline | Serum bone formation marker |
| C-telopeptide concentration | Baseline | Serum bone resorption marker |
| Fasting glucose concentration | Baseline | Diabetes control |
| Fasting Hemoglobin A1c concentration | Baseline | Diabetes control |
| Insulin concentration | Baseline | Hormone involved in bone metabolism |
| Body composition measured as visceral and subcutaneous adipose tissue | Baseline | Measured by computed tomography (CT) |
| Serum 25-hydroxyvitamin D concentration | Baseline | Hormone involved in bone metabolism |
| Bone marrow adiposity | Baseline | Measured by computed tomography (CT) |
| Upper extremity muscle strength measured by grip force in kg | Baseline | Measured using Jamar Hydraulic Hand Dynamometer |
| Lower extremity muscle strength measured by peak torque generated by knee extension | Baseline | Measured using Biodex isokinetic dynamometer |
| Functional mobility measured by time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down. | Baseline | Measured using Timed Up and Go test. |
| Functional exercise capacity measured by total distance ambulated during a 6 minute time period | Baseline | Measured using Six Minute Walk Test |
| Self-reported physical activity measured in metabolic equivalents (MET) | Baseline | Measured using the International Physical Activity Questionnaire |
| Cutaneous Advanced glycation end products (AGEs) measurement | Baseline | Measured by measured by AGE Reader |
| Physical activity measured by total activity and time spent in different intensities of exercise measured over 7 consecutive days | Baseline | Actigraph GT3X+ Accelerometer |
| Functional balance score obtained using multidimensional balance assessment. Higher scores indicate better balance abilities | Baseline | Fullerton Advanced Balance (FAB) Scale |
| Physical health | Baseline | SF-12 |
| Community Participation Restriction | Baseline | Life-space mobility assessment |
| Health-related quality of life | Baseline | How are you today? Visual analogue scale |
| Body composition measured by fat and lean mass | Baseline | Measured using dual-energy X-ray absorptiometry (DXA) |
| Parathormone concentration | Baseline | Hormone involved in bone metabolism |
| Estradiol concentration | Baseline | Hormone involved in bone metabolism |
Countries
Canada
Outcome results
None listed